3-hydroxymethyl-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine | 113209-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-hydroxymethyl-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
• 英文别名: [2-methyl-4-(3-nitrophenyl)-6-phenylpyridin-3-yl]methanol
• CAS: 113209-42-0
• 化学式: C₁₉H₁₆N₂O₃
• 分子量: 320.348
• InChiKey: KZOPWJCZEFHQRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  78.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-hydroxymethyl-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine 在 三溴化磷 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以24.9%的产率得到3-bromomethyl-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
  参考文献：
  名称：

  Studies on Cerebral Protective Agents. IV. Synthesis of Novel 4-Arylpyridine and 4-Arylpyridazine Derivatives with Anti-anoxic Activity.

  摘要：

  在寻找新的脑保护剂的过程中，合成了一系列具有氨基基团在吡啶（或吡嗪）环C-3位的4-(3或4-硝基苯基)-6-苯基吡啶（或吡嗪）和2-(3-硝基苯基)-6-苯基吡啶，通过相应的新型1,4-二氢衍生物合成，并在小鼠中测试其抗缺氧（AA）活性。四种化合物（2c、2f、3a、4a）在32 mg/kg的腹腔注射剂量下表现出显著的AA活性。这些结果表明，吡啶（或吡嗪）环C-3位与含氮碱性基团之间的四原子连接似乎也是表达AA活性的先决条件。

  DOI：

  10.1248/cpb.41.156
• 作为产物：
  描述：

  ethyl 1,4-dihydro-2-methyl-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxylate 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 、 氯仿 为溶剂， 反应 1.0h， 生成 3-hydroxymethyl-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
  参考文献：
  名称：

  Studies on Cerebral Protective Agents. IV. Synthesis of Novel 4-Arylpyridine and 4-Arylpyridazine Derivatives with Anti-anoxic Activity.

  摘要：

  在寻找新的脑保护剂的过程中，合成了一系列具有氨基基团在吡啶（或吡嗪）环C-3位的4-(3或4-硝基苯基)-6-苯基吡啶（或吡嗪）和2-(3-硝基苯基)-6-苯基吡啶，通过相应的新型1,4-二氢衍生物合成，并在小鼠中测试其抗缺氧（AA）活性。四种化合物（2c、2f、3a、4a）在32 mg/kg的腹腔注射剂量下表现出显著的AA活性。这些结果表明，吡啶（或吡嗪）环C-3位与含氮碱性基团之间的四原子连接似乎也是表达AA活性的先决条件。

  DOI：

  10.1248/cpb.41.156

文献信息

• Morpholine containing pyridine compounds, compositions and use
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04857527A1

  公开（公告）日：1989-08-15

  An N-containing heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted with hydroxy, halogen or a heterocyclic group, carboxy, esterified carboxy, carbamoyl optionally substituted with heterocyclic(lower)alkyl or lower alkylamino(lower)alkyl, N-containing heterocycliccarbonyl optionally substituted with lower alkyl, or ureido optionally substituted with lower alkylamino(lower)alkyl, and R.sup.3 is hydrogen or halogen; R.sup.2 is phenyl substituted with nitro, and X is .dbd.N--or ##STR2## in which R.sup.4 is lower alkyl or halo(lower)alkyl, or is taken together with R.sup.1 to form an N-containing heterocyclic group optionally substituted with oxo and lower alkylamino(lower)alkyl; or R.sup.2 is lower alkyl, and X is ##STR3## in which R.sup.4 is phenyl substituted with nitro; and a pharmaceutically acceptable salt thereof, processes for the preparation thereof and pharmaceutical (e.g. antihypertension) compositions comprising the same.

  一种含氮杂环化合物，化学式为：##STR1##其中R.sup.1是较低的烷基，可选择地取代为羟基、卤素或杂环基，羧基、酯化羧基、羰基取代的羰基，可选择地取代为杂环(较低)烷基或较低烷基氨基(较低)烷基的含氮杂环羰基，可选择地取代为较低烷基的含氮杂环羰基，或可选择地取代为较低烷基氨基(较低)烷基的脲基，R.sup.3是氢或卤素；R.sup.2是取代硝基的苯基，X是.dbd.N--或##STR2##其中R.sup.4是较低的烷基或卤代(较低)烷基，或与R.sup.1共同形成可选择地取代为氧代和较低烷基氨基(较低)烷基的含氮杂环基；或R.sup.2是较低烷基，X是##STR3##其中R.sup.4是取代硝基的苯基；以及其药学上可接受的盐，其制备方法和包含相同的药物(例如抗高血压)组合物。
• Diphenylpyridine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04831030A1

  公开（公告）日：1989-05-16

  The invention relates to compounds for treatment of hypertension, and cardiovascular and cerebrovascular diseases, which compounds are of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, and R.sup.3 is hydrogen or halogen; R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl or halo(lower)alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substitured with nitro; and a pharmaceutically acceptable salt thereof.

  该发明涉及用于治疗高血压、心血管和脑血管疾病的化合物，该化合物的结构如下：##STR1##其中R.sup.1是哌嗪基(较低)烷基，与哌嗪基(较低)烷基取代的氨甲酰基，或哌嗪基羰基，其中哌嗪基中的哌嗪基可能被较低烷基取代，R.sup.3是氢或卤素；R.sup.2是取代硝基的苯基，R.sup.4是较低烷基或卤(较低)烷基；或R.sup.2是较低烷基，R.sup.4是取代硝基的苯基；以及其药用可接受的盐。
• N-containing heterocyclic compounds, and composition comprising the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04990507A1

  公开（公告）日：1991-02-05

  The invention relates to a pharmaceutical composition as a therapeutic agent for ischemic disease comprising a compound of the formula ##STR1## wherein R.sup.1 is carbamoyl substituted with morpholino (lower) alkyl, thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl; and R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substituted with nitro; with proviso that R.sup.1 is carbamoyl substituted with thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl when R.sup.4 is lower alkyl; or its salt, as an active ingredient, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.

  本发明涉及一种药物组合物，作为缺血性疾病的治疗剂，包括一种化合物，其化学式为##STR1##其中R.sup.1是取代为吗啡啶基(lower)烷基、硫代吗啡啶(lower)烷基或(lower)烷基氨基(lower)烷基的氨基甲酰基；或取代为(lower)烷基氨基(lower)烷基的尿素基；R.sup.2是取代为硝基的苯基，而R.sup.4是(lower)烷基；或者R.sup.2是(lower)烷基，而R.sup.4是取代为硝基的苯基；但是当R.sup.4是(lower)烷基时，R.sup.1为取代为硫代吗啡啶(lower)烷基或(lower)烷基氨基(lower)烷基的氨基甲酰基或取代为(lower)烷基氨基(lower)烷基的尿素基；与一种药学上可接受的、基本无毒的载体或赋形剂结合使用，作为活性成分。
• Di phenylpyridazine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04931453A1

  公开（公告）日：1990-06-05

  The invention relates to diphenylpyridazine compounds useful in the treatment of cerebrovascular disease, of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, R.sup.2 is phenyl substituted with nitro, and R.sup.3 is hydrogen or halogen, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种用于治疗脑血管疾病的二苯吡嗪化合物，其化学式为：##STR1## 其中R.sup.1是哌嗪基（较低）烷基，用哌嗪基（较低）烷基取代的氨基甲酰基，或哌嗪基甲酰基，其中哌嗪基可以被较低烷基取代；R.sup.2是取代有硝基的苯基；R.sup.3是氢或卤素，或其药学上可接受的盐。
• N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0228845A2

  公开（公告）日：1987-07-15

  An N-containing heterocyclic compound of the formula: I wherein R' is lower alkyl optionally substituted with hydroxy, halogen or a heterocyciic group, carboxy, esterified carboxy, carbamoyl optionally substituted with heterocyclic(lower)alkyl or lower alkylamino(lower)alkyl, N-containing heterocycliccarbonyl optionally substituted with lower alkyl, or ureido optionally substituted with lower alkylamino(lower)alkyl, and R3 is hydrogen or halogen; R2 is phenyl substituted with nitro, and X is = N-or in which R' is lower alkyl or halo (lower) alkyl, or is taken together with R' to form an N-containing heterocyclic group optionally substituted with oxo and lower alkylamino(lower)alkyl; or R2 is lower alkyl, and X is in which R4 is phenyl substituted with nitro; and a pharmaceutically acceptable salt thereof, processes for the preparation thereof and composition comprising the same.

  式中的含 N 杂环化合物：I 其中 R'是任选被羟基、卤素或杂环基取代的低级烷基、羧基、酯化羧基、任选被杂环（低级）烷基或低级烷基氨基（低级）烷基取代的氨基甲酰基、任选被低级烷基取代的含 N 杂环羰基或任选被低级烷基氨基（低级）烷基取代的脲基，以及 R3 是氢或卤素； R2 是被硝基取代的苯基，以及 X 是 = N-or 其中 R'是低级烷基或卤代（低级）烷基，或与 R'一起形成可选被氧代和低级烷基氨基（低级）烷基取代的含 N 杂环基团；或 R2 是低级烷基，且 X 是 其中 R4 是被硝基取代的苯基； 及其药学上可接受的盐、制备工艺和包含这些成分的组合物。